PCL Retention Versus Sacrifice During Total Knee Replacement With a Medial Pivot Prosthesis
Retention vs Sacrifice of PCL in TKA With a Medial Pivot Prosthesis: a Prospective, Randomized Trial.
otal knee replacement is a common treatment for patients with severe knee osteoarthritis when non-surgical treatments no longer provide adequate relief. During total knee replacement, surgeons may either preserve or remove the posterior cruciate ligament (PCL), a ligament located inside the knee. Both approaches are used in clinical practice, but the effect of PCL preservation or removal when using a medial-pivot knee prosthesis is not fully established.
This study will compare two surgical approaches in patients undergoing total knee replacement with the same medial-pivot prosthesis. Participants will be randomly assigned to either PCL retention or PCL sacrifice during surgery.
The main purpose of the study is to determine whether retaining or removing the PCL affects how patients perceive and function with their artificial knee. The primary outcome will be the Forgotten Joint Score-12 (FJS-12) at 24 months after surgery, which assesses how much patients are aware of their artificial knee during everyday activities. Other outcomes will include knee function, pain, range of motion, stability, patient satisfaction, complications, and radiographic findings.
The study hypothesis is that there may be a difference in patient-reported outcomes between PCL retention and PCL sacrifice when a medial-pivot knee prosthesis is used. Participants will be evaluated before surgery and at 3, 6, 12, and 24 months after surgery.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Thessaly
-
Larissa, Thessaly, Greece, 41500
- University Hospital of Larissa
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Age 50 to 85 years. Symptomatic end-stage osteoarthritis of the knee, confirmed clinically and radiographically.
Failure of conservative treatment for knee osteoarthritis. Suitable candidate for primary total knee arthroplasty. Able to participate in and complete the planned postoperative follow-up schedule
Exclusion Criteria:
Previous surgery on the affected knee. Inflammatory arthritis. Active infection. Severe lower-limb deformity greater than 15 degrees. Neurological disease affecting lower-limb function.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: PCL retention
Participants randomized to this arm will undergo primary total knee arthroplasty using a medial-pivot knee prosthesis with retention of the posterior cruciate ligament (PCL). |
Participants randomized to this arm will undergo primary total knee arthroplasty using a medial-pivot knee prosthesis (MicroPort Evolution) with retention of the posterior cruciate ligament (PCL). The procedure will be performed according to the standardized surgical technique used by the Orthopaedic Department. |
|
Active Comparator: PCL sacrifice
Participants randomized to this arm will undergo primary total knee arthroplasty using the same medial-pivot knee prosthesis, with sacrifice (removal) of the posterior cruciate ligament (PCL). |
Participants randomized to this arm will undergo primary total knee arthroplasty using a medial-pivot knee prosthesis (MicroPort Evolution) with sacrifice of the posterior cruciate ligament (PCL). The procedure will be performed according to the standardized surgical technique used by the Orthopaedic Department. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Forgotten Joint Score-12 (FJS-12) at 24 Months After Total Knee Arthroplasty
Time Frame: 24 months after total knee arthroplasty
|
24 months after total knee arthroplasty
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Knee Society Score (KSS) at 24 Months After Total Knee Arthroplasty
Time Frame: 24 months after total knee arthroplasty
|
Assessment of knee function using the Knee Society Score |
24 months after total knee arthroplasty
|
|
Oxford Knee Score (OKS) at 24 Months After Total Knee Arthroplasty
Time Frame: 24 months after total knee arthroplasty
|
Assessment of patient-reported knee function using the Oxford Knee Score. |
24 months after total knee arthroplasty
|
|
Change From Baseline in Knee Range of Motion at 24 Months After Total Knee Arthroplasty
Time Frame: Baseline and 24 months after total knee arthroplasty
|
Assessment of change in knee range of motion from the preoperative baseline. |
Baseline and 24 months after total knee arthroplasty
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 11/06/2026-27262
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.